CLD-423
/ Caldera Therapeutics, Qyuns Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
January 14, 2026
Caldera Therapeutics Launches with $112.5 Million and Announces First Subjects Dosed in Phase 1 Trial of First-In-Class Bispecific Antibody CLD-423 for Inflammatory Bowel Disease
(Businesswire)
Financing • Trial status • Inflammatory Bowel Disease
1 to 1
Of
1
Go to page
1